Flow cytometric immunophenotyping of regulatory T cells in chronic lymphocytic leukemia: comparative assessment of various markers and use of novel antibody panel with CD127 as alternative to transcription factor FoxP3

References

• Beyer M, Kochanek M, Darabi K, . Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005;106:2018–2025.
   PubMed Web of Science ®Google Scholar
• Giannopoulos K, Schmitt M, Kowal M, . Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol Rep 2008;20:677–682.
   PubMed Web of Science ®Google Scholar
• Deutsch V, Perry C, Polliack A. Expansion of regulatory T cells in B chronic lymphocytic leukemia: enhanced “brakes” on host immunity. Leuk Lymphoma 2009;50:687–688.
   PubMed Web of Science ®Google Scholar
• Jak M, Mous R, Remmerswaal EBM, . Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia. Leuk Lymphoma 2009;50:788–801.
   PubMed Web of Science ®Google Scholar
• D’Arena G, Laurenti L, Minervini MM, . Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. Leuk Res 2011;35:363–368.
   PubMed Web of Science ®Google Scholar
• Diehl LF, Karnell LH, Menck HR. The American College of Surgeons Commission on Cancer and the American Cancer Society. The National Cancer Data Base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia. Cancer 1999;86:2684–2692.
   PubMed Web of Science ®Google Scholar
• Agrawal N, Naithani R, Mahapatra M, . Chronic lymphocytic leukemia in India–a clinico-hematological profile. Hematology 2007; 12:229–233.
   PubMed Web of Science ®Google Scholar
• Naresh KN, Agarwal B, Nathwani BN, . Use of the World Health Organization (WHO) classification of non-Hodgkin's lymphoma in Mumbai, India: a review of 200 consecutive cases by a panel of five expert hematopathologists. Leuk Lymphoma 2004;45:1569–1577.
   PubMed Web of Science ®Google Scholar
• Bhutani M, Vora A, Kumar L, . Lympho-hemopoietic malignancies in India. Med Oncol 2002;19:141–150.
   PubMed Web of Science ®Google Scholar
• Nair CN, Chougule A, Dhond S, . Trisomy 12 in chronic lymphocytic leukemia–geographical variation. Leuk Res 1998;22: 313–317.
   PubMed Web of Science ®Google Scholar
• Montserrat E, Rozman C. Chronic lymphocytic leukemia: present status. Ann Oncol 1995;6:219–235.
   PubMed Web of Science ®Google Scholar
• Gershon RK, Kondo K. Infectious immunological tolerance. Immunology 1971;21:903–914.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Sakaguchi N, Asano M, . Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151–1164.
   PubMed Web of Science ®Google Scholar
• Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299: 1057–1061.
   PubMed Web of Science ®Google Scholar
• Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003;4:330–336.
   PubMed Web of Science ®Google Scholar
• Rouse BT. Regulatory T cells in health and disease. J Intern Med 2007;262:78–95.
   PubMed Web of Science ®Google Scholar
• Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006; 108:804–811.
   PubMed Web of Science ®Google Scholar
• Franzke A, Hunger JK, Dittmar KEJ, . Regulatory T-cells in the control of immunological diseases. Ann Hematol 2006;85:747–758.
   PubMed Web of Science ®Google Scholar
• Baecher-Allan C, Brown JA, Freeman GJ, . CD4+CD25high regulatory cells in human peripheral blood. J Immunol 2001;167: 1245–1253.
   PubMed Web of Science ®Google Scholar
• Liu W, Putnam AL, Xu-Yu Z, . CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006;203:1701–1711.
   PubMed Web of Science ®Google Scholar
• Seddiki N, Santner-Nanan B, Martinson J, . Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006;203:1693–1700.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Sakaguchi N, Shimizu J, . Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001;182:18–32.
   PubMed Web of Science ®Google Scholar
• Varona R, Cadenas V, Lozano M, . CCR6 regulates the function of alloreactive and regulatory CD4+ T cells during acute graft-versus-host disease. Leuk Lymphoma 2006;47:1469–1476.
   PubMed Web of Science ®Google Scholar
• Coghill JM, Carlson MJ, Moran TP, . The biology and therapeutic potential of natural regulatory T-cells in the bone marrow transplant setting. Leuk Lymphoma 2008;49:1860–1869.
   PubMed Web of Science ®Google Scholar
• Onizuka S, Tawara I, Shimizu J, . Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999;59:3128–3133.
   PubMed Web of Science ®Google Scholar
• Lee N-R, Song E-K, Jang KY, . Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis. Leuk Lymphoma 2008;49:247–256.
   PubMed Web of Science ®Google Scholar
• Szczepanski MJ, Szajnik M, Czystowska M, . Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res 2009;15:3325–3332.
   PubMed Web of Science ®Google Scholar
• Wang X, Zheng J, Liu J, . Increased population of CD4(+)CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients. Eur J Haematol 2005;75:468–476.
   PubMed Web of Science ®Google Scholar
• Beyer M, Kochanek M, Giese T, . In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood 2006;107:3940–3949.
   PubMed Web of Science ®Google Scholar
• Mittal S, Marshall NA, Duncan L, . Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma. Blood 2008;111:5359–5370.
   PubMed Web of Science ®Google Scholar
• Rojas JM, Wang L, Owen S, . Naturally occurring CD4+ CD25+ FOXP3+ T-regulatory cells are increased in chronic myeloid leukemia patients not in complete cytogenetic remission and can be immunosuppressive. Exp Hematol 2010;38:1209–1218.
   PubMed Web of Science ®Google Scholar
• Weiss L, Melchardt T, Egle A, . Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia. Cancer 2011;117:2163–2169.
   PubMed Web of Science ®Google Scholar
• Marshall NA, Christie LE, Munro LR, . Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004;103:1755–1762.
   PubMed Web of Science ®Google Scholar
• Yang Z-Z, Novak AJ, Stenson MJ, . Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 2006;107:3639–3646.
   PubMed Web of Science ®Google Scholar
• Perry C, Herishanu Y, Hazan-Halevy I, . Reciprocal changes in regulatory T cells and Th17 helper cells induced by exercise in patients with chronic lymphocytic leukemia. Leuk Lymphoma 2012;53: 1807–1810.
   PubMed Web of Science ®Google Scholar
• Lutsiak MEC, Semnani RT, De Pascalis R, . Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005;105:2862–2868.
   PubMed Web of Science ®Google Scholar
• Giannopoulos K, Dmoszynska A, Kowal M, . Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia. Leukemia 2009;23:1771–1778.
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L, . Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942–949.
   PubMed Web of Science ®Google Scholar